Variations in Resources Among Radiation Oncology Residency Programs in the United States.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
07
05
2020
revised:
21
06
2020
accepted:
03
08
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
The purpose of this research was to assess the existing variations in the residency training resources among radiation oncology (RO) residency programs in the United States. We queried each residency program website and Fellowship Residency Electronic Interactive Data Access System website (www.freida.ama-assn.org) to obtain information on faculty and available treatment modalities. The data were continuously updated, most recently as of April 30, 2019. A total of 94 RO residency programs were identified during the academic year 2018-2019, and data were collected. The median number of attending physicians was 13 (range, 4 -71). The median number of physicists and biologists were 9 and 3, respectively. The conventional techniques, including 3 dimensional conformal radation therapy, intensity modulated radiation therapy, electron therapy, and stereotactic body radiation therap/stereotactic radiosurgery, were available in all residency programs. In terms of specialized external beam radiation therapy machines, gamma knife, CyberKnife, and magnetic resonance imaging (MRI) linear accelerator were available in 49 (52%), 21(22%), and 7 (8%) programs, respectively. Only 19 programs (20%) had in-house proton therapy availability; however, 37 programs (39%) offered proton therapy training via resident rotation at an affiliated institution. Prostate, gynecologic, and breast brachytherapy were available in 81 (86%), 82 (87%), and 58 (62%) programs, respectively. Eighty-one (86%) programs reported to have high dose rate, and only 20 (21%) programs had low dose rate brachytherapy. Our study found that marked variations exist among RO residency programs in the United States during academic year 2018-2019 and will serve as a baseline for future intervention.
Identifiants
pubmed: 33521395
doi: 10.1016/j.adro.2020.08.001
pii: S2452-1094(20)30212-8
pmc: PMC7820023
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100544Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM121334
Pays : United States
Informations de copyright
© 2020 The Author(s).
Références
Pract Radiat Oncol. 2016 May-Jun;6(3):160-165
pubmed: 26723548
J Clin Oncol. 2015 Mar 20;33(9):980-2
pubmed: 25667278
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):557-560
pubmed: 30612963
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):789-791
pubmed: 29976490
Brachytherapy. 2013 Nov-Dec;12(6):622-7
pubmed: 23973187
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9
pubmed: 23849695